课题基金 / 基金详情

Determinants of Melanocyte Transformation and Melanoma Progression

Determinants of Melanocyte Transformation and Melanoma Progression
黑色素细胞转化和黑色素瘤进展的决定因素
批准号:
7965428
负责人:
thomas j hornyak
金额:
$47.13万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

thomas j hornyak的其他基金

相似基金

相关文献

中文摘要
翻译
今年,我们的工作重点是表征关键polycomb的表达 人黑素细胞、黑素细胞痣和黑素瘤细胞中的蛋白质。多梳蛋白是 表观遗传基因阻遏物,与抑制Hox基因表达的蛋白质相关, 果蝇的发育,其功能是通过与特定的 组蛋白氨基酸残基。我们正在确定其中两个 BMI-1和EZH 2蛋白在恶性黑色素瘤中起作用。BMI-1和EZH 2是 大分子复合物Polycomb抑制复合物(PRC)-1和-2。组蛋白 PRC 2中EZH 2的甲基转移酶活性产生稳定的三甲基化衍生物, 核心核小体的组蛋白3上的赖氨酸27,其被含有BMI-1的PRC 1识别, 导致表观遗传基因抑制。以前,我们对polycomb蛋白表达的分析 在正常黑素细胞、黑素细胞痣和体内黑色素瘤中,BMI-1表达 在黑素细胞、黑素细胞痣细胞和转移性黑色素瘤中。相反,EZH 2是 只在黑色素瘤细胞中表达,在黑色素细胞或痣中不表达。正常皮肤是在一个 CCR皮肤科分支综合方案,痣是从患者获得的许多 黑素细胞痣登记在临床方案06-C-0060(托马斯J. Hornyak,M.D.,哲学博士、 主要研究者),转移性黑色素瘤标本从NCI/CCR获得 外科分支。EZH 2在正常人和正常人之间的表达存在显著差异, 痣相关黑素细胞和恶性黑色素瘤细胞的研究使我们假设EZH 2 表达是黑色素瘤恶性进展的决定因素。大量的 今年的工作是检验这一假设。使用基因工程 转化的人黑素细胞系,从Robert温伯格博士的实验室获得, MIT,我们研究了使用RNA干扰从这些细胞中消除EZH 2的影响。我们 发现EZH 2耗尽的细胞表现出细胞增殖速率降低,并且细胞增殖速率增加。 细胞衰老标记物衰老相关β-半乳糖苷酶(SA)的表达 β-半乳糖)。它们还表现出变宽、变平的形态。EZH 2耗尽的细胞还 当在软琼脂中生长时形成较少的细胞集落, 引入免疫受损小鼠中。这些结果表明,EZH 2表达在 转化的人黑素细胞是这些细胞致瘤性的重要因素。到 概括这些发现,我们已经扩展了这些实验,以确定EZH 2的影响 在建立的人黑素瘤细胞系中的消耗。我们现在已经确定,减少EZH 2 在人黑色素瘤细胞系亚群中的表达降低了它们的增殖速率, 增加SA β-gal的表达。目前,我们的工作重点是验证 EZH 2的这些作用的机制。我们认为在黑色素瘤细胞中,EZH 2抑制了一个基因, 或一组基因,它们本身是癌基因诱导衰老的决定因素。我们 目前正在研究EZH 2缺失对先前涉及的候选基因的影响, 癌基因诱导的衰老,并评估通过微阵列鉴定的其他基因 筛查他们的活动。我们还进行了实验以评估 黑色素瘤细胞中的BMI-1。我们已经确定了2个人黑色素瘤细胞系敏感的消耗 BMI-1在这些细胞中,BMI-1缺失导致细胞凋亡率降低。 增殖我们目前正在计划实验,以确定是否有一些相同的 我们已经显示的受EZH 2耗尽影响的肿瘤细胞的特征也被 受BMI-1消耗的影响。此前,我们启动了一个项目,旨在探索 热休克蛋白抑制剂17-烯丙氨基-17-去甲氧基格尔德霉素(17-AAG)作用 90(HSP 90),对黑色素瘤细胞中致癌激酶BRAF和CRAF的作用。我们发现17-AAG可以 在5/5的人黑素瘤细胞系中通过诱导 BRAF、BRAF和CRAF的降解,或通过HSP 90:BRAF复合物抑制BRAF活性。 我们正在计划完成实验,以详细说明这些效应的机制。
英文摘要
This year our efforts have been focused upon characterizing expression of key polycomb proteins in human melanocytes, melanocytic nevi, and melanoma cells. Polycomb proteins are epigenetic gene repressors, related to proteins repressing Hox gene expression during Drosophila development, that function through interacting with and modifying with specific histone amino acid residues. We are determining the functional role that two of these proteins, BMI-1 and EZH2, play in malignant melanoma. BMI-1 and EZH2 are members of the macromolecular complexes Polycomb Repressor Complex (PRC)-1 and -2, respectively. The histone methyltransferase activity of EZH2 in PRC2 creates the stable trimethylated derivative of lysine 27 on histone 3 of the core nucleosome that is recognized by BMI-1-containing PRC1, leading to epigenetic gene repression. Previously, our analysis of polycomb protein expression in normal melanocytes, melanocytic nevi, and melanomas in vivo showed that BMI-1 was expressed in melanocytes, melanocytic nevus cells, and metastatic melanoma. In contrast, EZH2 was expressed only in melanoma cells, not in melanocytes or nevi. Normal skin was obtained under a CCR Dermatology Branch omnibus protocol, nevi were obtained from patients with numerous melanocytic nevi enrolled in a clinical protocol, 06-C-0060 (Thomas J. Hornyak, M.D., Ph.D., Principal Investigator), and metastatic melanoma specimens were obtained from the NCI/CCR Surgery Branch. The marked difference in EZH2 expression between both normal and nevus-associated melanocytes and malignant melanoma cells led us to hypothesize that EZH2 expression is a determinant of malignant progession in melanoma. A substantial amount of effort was placed this year into testing this hypothesis. Using a genetically engineered transformed human melanocyte cell line, obtained from the laboratory of Dr. Robert Weinberg at MIT, we investigated the effects of depleting EZH2 from these cells using RNA interference. We found that EZH2-depleted cells demonstrated a reduced rate of cell proliferation and increased expression of the cellular senescence marker senescence-associated beta-galactosidase (SA beta-gal). They also exhibited a broadened, flattened morphology. EZH2-depleted cells also form fewer colonies of cells when grown in soft agar and form tumors more slowly following introduction into immunocompromised mice. These results suggest that EZH2 expression in transformed human melanocytes is an important factor in the tumorigenicity of these cells. To generalize these findings, we have extended these experiments to determine the effects of EZH2 depletion in established human melanoma cell lines. We have now determined that reducing EZH2 expression in a subset of human melanoma lines decreases their proliferation rate and increases expression of SA beta-gal. Currently our efforts our focused upon validating a mechanism for these effects of EZH2. We propose that in melanoma cells, EZH2 represses a gene or set of genes that are themselves determinants of oncogene-induced senescence. We are currently examining the effect of EZH2 depletion on candidate genes previously implicated in oncogene-induced senescence, and also evaluating other genes identified through a microarray screen for their activities. We have also performed experiments to evaluate the activity of BMI-1 in melanoma cells. We have identified 2 human melanoma cell lines sensitive to depletion of BMI-1. In these cells, BMI-1 depletion results in a decrease of the rate of cellular proliferation. We are currently planning experiments to determine whether some of the same characteristics of tumor cells that we have shown are affected by depletion of EZH2 are also affected by depletion of BMI-1. Previously, we initiated a project designed to explore the effect of 17-allylaino-17-demethoxygeldanamycin (17-AAG), an inhibitor of heat shock protein 90 (HSP90), on the oncogenic kinases BRAF and CRAF in melanoma cells. We found that 17-AAG can inhibit melanoma cell proliferation in 5/5 human melanoma cell lines by inducing the degradation of BRAF, BRAF and CRAF, or inhibiting BRAF activity through an HSP90:BRAF complex. We are planning to complete experiments that will specify the mechanism for these effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Malignant Progression in Human Melanoma
  • 批准号:
    7338697
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    thomas j hornyak
  • 依托单位:
Regulation of Melanocyte Development and Differentiation
  • 批准号:
    7292188
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    thomas j hornyak
  • 依托单位:
Isolation, Characterization, and Behavior of Melanocyte Stem Cells
  • 批准号:
    7965565
  • 项目类别:
  • 资助金额:
    $47.13万
  • 财政年份:
    --
  • 负责人:
    thomas j hornyak
  • 依托单位:
Dermatoscopy in the Evaluation of Pigmented Lesions
  • 批准号:
    8349125
  • 项目类别:
  • 资助金额:
    $6.55万
  • 财政年份:
    --
  • 负责人:
    thomas j hornyak
  • 依托单位:
国内基金
海外基金
Cd(II)在NH2-Agar/PSS双网络水凝胶上的吸附行为及资源化工艺研究
  • 批准号:
    51708204
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2017
  • 负责人:
    周贵寅
  • 依托单位: